Literature DB >> 21733092

Liver transplantation using donor organs with markedly elevated liver enzymes: how far can we go?

Sonia Radunz1, Andreas Paul, Knut Nowak, Jürgen W Treckmann, Fuat H Saner, Zoltan Mathé.   

Abstract

BACKGROUND: The disparity between the demand for solid organs and the current supply is a growing problem for patients with end-stage liver disease. To overcome organ shortage, extended criteria donor organs are also accepted for liver transplantation. AIMS: We here unprecedentedly report the clinical course of patients receiving livers with markedly elevated liver enzymes.
METHODS: Between November 2007 and December 2010, 15 donor livers with markedly elevated liver enzymes [median aspartate aminotransferase (AST) 1400 (500-7538) U/l, median alanine aminotransferase (ALT) 1026 (308-9179) U/l] were offered to our transplant centre. Based on elaborate judgment, seven of these donor livers were rejected and eight donor livers were transplanted.
RESULTS: All eight transplanted patients showed a liver enzyme peak on the day of surgery (AST 2076 ± 1808 U/l, ALT 1087 ± 833 U/l) and a statistically significant decrease from day 0 to day 7 post-liver transplantation. INR decreased and platelet count increased statistically significantly within 1 week after liver transplantation. The patients were discharged from the hospital 28 ± 11 days after liver transplantation in good clinical condition.
CONCLUSIONS: These data demonstrate that using donor livers with markedly elevated liver enzymes may be an acceptable option to expand the donor pool. Universal objective parameters for acceptance should be defined in future studies.
© 2011 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21733092     DOI: 10.1111/j.1478-3231.2011.02525.x

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  8 in total

1.  Trends in deceased donor liver enzymes prior to transplant: The impact on graft selection and outcomes.

Authors:  Melissa G Kaltenbach; Michael O Harhay; Peter L Abt; David S Goldberg
Journal:  Am J Transplant       Date:  2019-09-24       Impact factor: 8.086

2.  Graft Reconditioning before Liver Transplantation.

Authors:  Dieter P Hoyer; Thomas Minor
Journal:  Visc Med       Date:  2016-07-29

Review 3.  Changing pattern of donor selection criteria in deceased donor liver transplant: a review of literature.

Authors:  Dronacharya Routh; Sudeep Naidu; Sanjay Sharma; Priya Ranjan; Rajesh Godara
Journal:  J Clin Exp Hepatol       Date:  2013-12-05

4.  Medical students' education on organ donation and its evaluation during six consecutive years: results of a voluntary, anonymous educational intervention study.

Authors:  Sonia Radunz; Tamás Benkö; Sabrina Stern; Fuat H Saner; Andreas Paul; Gernot M Kaiser
Journal:  Eur J Med Res       Date:  2015-03-12       Impact factor: 2.175

5.  Transplantation of Deceased Donor Livers With Elevated Levels of Serum Transaminases at Shiraz Transplant Center.

Authors:  Nasir Fakhar; Saman Nikeghbalian; Kourosh Kazemi; Ali Reza Shamsayeefar; Siavash Gholami; Amir Kasraianfard; Seyed Ali Malek-Hosseini
Journal:  Hepat Mon       Date:  2016-10-08       Impact factor: 0.660

6.  Liver Transplantation From Donors With a History of Malignancy: A Single-Center Experience.

Authors:  Tamas Benkö; Dieter P Hoyer; Fuat H Saner; Jürgen W Treckmann; Andreas Paul; Sonia Radunz
Journal:  Transplant Direct       Date:  2017-10-18

7.  A simplified subnormothermic machine perfusion system restores ischemically damaged liver grafts in a rat model of orthotopic liver transplantation.

Authors:  Tim A Berendsen; Bote G Bruinsma; Jungwoo Lee; Vincent D'Andrea; Qiang Liu; Maria-Louisa Izamis; Korkut Uygun; Martin L Yarmush
Journal:  Transplant Res       Date:  2012-05-09

8.  The Graz Liver Allocation Strategy-Impact of Extended Criteria Grafts on Outcome Considering Immunological Aspects.

Authors:  Judith Kahn; Gudrun Pregartner; Alexander Avian; Daniela Kniepeiss; Helmut Müller; Peter Schemmer
Journal:  Front Immunol       Date:  2020-08-04       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.